Preview: Capricor Therapeutics’s Earnings

Capricor Therapeutics (NASDAQ:CAPR) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here’s what investors…

Capricor Therapeutics (NASDAQ:CAPR) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here’s what investors need to know before the announcement.

Analysts estimate that Capricor Therapeutics will report an earnings per share (EPS) of $-0.29.

Capricor Therapeutics bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.06, which was followed by a 21.66% increase in the share price the next day.

Here’s a look at Capricor Therapeutics’s past performance and the resulting price change:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.35 -0.32 -0.33 -0.29
EPS Actual -0.29 -0.31 -0.31 -0.26
Price Change % 21.66% -1.95% 1.9% -7.14%

eps graph

Stock Performance

Shares of Capricor Therapeutics were trading at $2.8 as of November 10. Over the last 52-week period, shares are down 30.72%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Capricor Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Ultragenyx Reports Preliminary 2023 Revenue; Guidance For 2024 Revenue And Cash Usage; Pipeline Updates And 2024 Milestones; Sees FY23 Revenue $430-$435M Vs $435.9M Est.; Sees FY24 Revenue $500M-$530M Vs $523.86M Est.; Year-End 2023 Cash Balance Of ~$7…

Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million2024 expected Total Revenue guidance

RARE